Orange capsicums contain the richest source of the orange pigment zeaxanthin, which is vital for central vision, according to a plant physiologist at The University of Queensland (UQ). Read more
Australia trial commences for ‘game-changer’ retinal disease eye drop
A clinical trial is under way in Australia for a novel eye drop treatment for retinal vascular diseases that could replace the current approach involving serial intravitreal injections into the back of the eye. Read more
Study reveals age optometrists are most comfortable fitting CLs in paediatric myopes
A new global myopia survey that involved Australian participants has revealed optometrists are comfortable with fitting children with contact lenses from 9-years-old while for parents the average age is 12. Read more
Aussie IRD study taps into gene therapy perceptions
Researchers from the Centre for Eye Research Australia and University of Melbourne have developed a world-first survey to gather the views of Australians with inherited retinal diseases (IRDs) on potential gene therapies. Read more
Local study finds keratoconus ‘extremely common’ in Down syndrome
A new study conducted in New Zealand has revealed keratoconus is prevalent in 30% to 38% of people with Down syndrome, suggesting that screening may be worthwhile for people with the genetic disorder. Read more
Chinese myopia-lockdown study a portent for Australia
A new phenomenon dubbed “quarantine myopia” is making waves in Australia in the wake of a Chinese study that found myopia prevalence was three times higher in six-year-olds during the COVID-19 pandemic. Read more
Low carb diet an antidote to type 2 diabetes?
An Australian researcher has contributed to a new study demonstrating that lower carbohydrate consumption can potentially put type 2 diabetes into remission. Read more
Presbyopia eye drop in final stage of clinical development
An ophthalmic pharmaceutical company has commenced two Phase 3 clinical studies to evaluate its eye drop candidate for presbyopia. Read more
Case report links COVID-19 with permanent vision loss
Ophthalmologists have documented what is believed to be the first reported case of permanent loss of visual acuity that may have been induced by SARS-CoV-2, the virus that causes COVID-19. Read more
Roche’s faricimab meets primary endpoint in DME trial
Swiss drug giant Roche is poised to pursue regulatory clearance for its new faricimab antibody for diabetic macular edema (DME) after it produced a similar effect to Eylea in twin clinical trials, but with half the dosing regimen in several patients. Read more